Clinical trials endpoints in oncology;Gli endpoint degli studi clinici in oncologia

Tumori

Volumn 83, Issue 6 SUPPL. 1, 1997, Pages

  Roila, Fausto ^a   Del Favero, Albano ^b   Ballatori, Enzo ^c  

^a Ospedale Policlinico   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Clinical benefit; Clinical trials endpoints; Quality of life; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; HUMAN; ONCOLOGY; PRESCRIPTION; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0031417488     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. American Society of Clinical Oncology: Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J. Clin. Oncol. 2: 671-670, 1996.
2. Burris III H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D.: Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreatic cancer: a randomized trial. J. Clin. Oncol. 15: 2403-2413, 1997.
3. Feld R.: Endpoints in cancer clinical trials: is there a need for measuring quality of life? Support Care Cancer, 3: 23-27, 1995.
4. Gelber R.D.: Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective. Ann. Oncol. 7: 335-337, 1996.
5. Italian Group for Antiemetic Research: On the relationship between nausea and vomiting in patients undergoing chemotherapy. Support Care Cancer, 2: 171-176, 1994.
6. McGuire W., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., Davidson M.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med., 334: 1-6, 1996.
7. O'Shaughnessy J.A., Wittes R.E., Burke G. Friedman M.A., Johnson J.R., Niederhuber J.E., Rothenberg M.L., Woodcock J., Chabner B.A., Temple R.: Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J. Clin. Oncol. 9: 2225-2232, 1991.
8. Roila F., Neri C., Palladino M.A.: Qualità della vita e protocolli terapeutici. In: Oncostress. L'operatore - il paziente, G. Ambrosini, S. Barni, L. Frontini, Eds., pp 135-146, 1994.
9. Rothenberg M.L., Moore M.J., Cripps M.C., Andersen J.S., Portenoy R.K., Burris III H.A., Green M.R., Tarassoff P.G., Brown T.D., Casper E.S., Storniolo A.M., Von Hoff D.D.: A phase II trial of gemcitabine in patients with 5FU-refractory pancreas cancer. Ann. Oncol. 7: 347-353, 1996.
10. Smith T.J., Hillner E., Desch C.E.: Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J. Natl. Cancer Inst., 85: 1460-1474, 1993.
11. Tannock I.F., Osoba D., Stockier M.R., Ernst D.S., Neville A.J., Moore M.J., Armitage G.R., Wilson J.J., Venner P.M., Coppin C.M.L., Murphy K.C.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol., 14: 1756-1764, 1996.
12. Verwedij J.: The benefit of clinical benefit: a European perspective. Ann. Oncol. 7: 333-334, 1996.